| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
The Arthritis Center, Department of Medicine, and
Department of Microbiology, Boston University School of Medicine, Boston, MA 02118; and
Department of Environmental Health, School of Public Health, Boston University School of Medicine, Boston, MA 02118
Bioactive Fas ligand (FasL)-expressing vesicles were generated (vesicle preparation, VP) from two cell lines overexpressing FasL. The effect of NOK-1 anti-FasL mAb (mouse IgG1) on the cytotoxicity of FasL VP against various targets was determined. At high concentrations (1–10 µg/ml), NOK-1 inhibited the cytotoxicity. By contrast, NOK-1 in the dose range of 1–100 ng/ml significantly enhanced cytotoxicity against the FcR+ LB27.4, M59, and LF+ targets, but not the FcR- Jurkat and K31H28 hybridoma T cell targets. The ability to enhance FasL VP-mediated cytotoxicity could be blocked by the FcR-specific mAb 2.4G2. Enhancement was also observed with FcR+ A20 B lymphoma but not with the FcR- A20 variant. Enhancement of FasL VP cytotoxicity was observed with five IgG anti-FasL mAbs, but not with an IgM anti-FasL mAb. Inhibition was observed with high doses of all mAb except the IgG anti-FasL mAb G247-4, which is specific to a segment outside the FasL binding site. Interestingly, under identical conditions but in the presence of 2.4G2, G247-4 inhibited the cytotoxicity of FasL VP. In addition, G247-4 inhibited the FasL VP-mediated killing of FcR- Jurkat. The data demonstrate that FasL-expressing bioactive vesicles display a property heretofore unknown in bioactive agents that express FasL-mediated cytotoxicity. The mechanism of the Ab-mediated, FcR-dependent enhancement of cytotoxicity of bioactive vesicles and its physiological significance are discussed.
This article has been cited by other articles:
|
|
 |
|
  X. Li, Y.-H. Liu, Y.-P. Zhang, S. Zhang, X. Pu, T. A. Gardner, M.-H. Jeng, and C. Kao Fas Ligand Delivery by a Prostate-Restricted Replicative Adenovirus Enhances Safety and Antitumor Efficacy Clin. Cancer Res., September 15, 2007; 13(18): 5463 - 5473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zuccato, E. J. Blott, O. Holt, S. Sigismund, M. Shaw, G. Bossi, and G. M. Griffiths Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation J. Cell Sci., January 1, 2007; 120(1): 191 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Gregory, S. Koh, E. Huang, R. R. Saff, A. Marshak-Rothstein, S. Mukai, and B. R. Ksander A Novel Treatment for Ocular Tumors Using Membrane FasL Vesicles to Activate Innate Immunity and Terminate Immune Privilege Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2495 - 2502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Xiao, X. Zhang, K. K. Mann, S. Jodo, L. Li, W. N. Jarjour, A. Marshak-Rothstein, D. H. Sherr, and S.-T. Ju Changes in sensitivity of peripheral lymphocytes of autoimmune gld mice to FasL-mediated apoptosis reveal a mechanism for the preferential deletion of CD4-CD8-B220+ T cells Int. Immunol., May 1, 2004; 16(5): 759 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Abrahams, S. L. Straszewski-Chavez, S. Guller, and G. Mor First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis Mol. Hum. Reprod., January 1, 2004; 10(1): 55 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Abrahams, S. L. Straszewski, M. Kamsteeg, B. Hanczaruk, P. E. Schwartz, T. J. Rutherford, and G. Mor Epithelial Ovarian Cancer Cells Secrete Functional Fas Ligand Cancer Res., September 1, 2003; 63(17): 5573 - 5581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu, A. J. Szalai, T. Zhou, K. R. Zinn, T. R. Chaudhuri, X. Li, W. J. Koopman, and R. P. Kimberly Fc{gamma}Rs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody-Based Therapeutics J. Immunol., July 15, 2003; 171(2): 562 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jodo, J. T. Kung, S. Xiao, D. V. Chan, S. Kobayashi, M. Tateno, R. Lafyatis, and S.-T. Ju Anti-CD95-induced Lethality Requires Radioresistant Fcgamma RII+ Cells. A NOVEL MECHANISM FOR FULMINANT HEPATIC FAILURE J. Biol. Chem., February 21, 2003; 278(9): 7553 - 7557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Xiao, S. Jodo, S.-s. J. Sung, A. Marshak-Rothstein, and S.-T. Ju A Novel Signaling Mechanism for Soluble CD95 Ligand. SYNERGY WITH ANTI-CD95 MONOCLONAL ANTIBODIES FOR APOPTOSIS AND NF-kappa B NUCLEAR TRANSLOCATION J. Biol. Chem., December 20, 2002; 277(52): 50907 - 50913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Hohlbaum, M. S. Gregory, S.-T. Ju, and A. Marshak-Rothstein Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors J. Immunol., December 1, 2001; 167(11): 6217 - 6224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jodo, S. Xiao, A. Hohlbaum, D. Strehlow, A. Marshak-Rothstein, and S.-T. Ju Apoptosis-inducing Membrane Vesicles. A NOVEL AGENT WITH UNIQUE PROPERTIES J. Biol. Chem., October 19, 2001; 276(43): 39938 - 39944. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
